• Intellia Therapeutics completed enrollment in its Phase 3 MAGNITUDE-2 trial of nexiguran ziclumeran for hereditary transthyretin amyloidosis with polyneuropathy.
• The placebo-controlled study will evaluate efficacy and safety in approximately 60 patients; enrollment completion is not a clinical outcome.
• The investigational, one-time gene-editing treatment targets liver production of transthyretin, aiming to halt or reverse disease progression.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intellia Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040800PRIMZONEFULLFEED9869049) on November 04, 2026, and is solely responsible for the information contained therein.